COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis – evidence summary (ES26)

This review identified no evidence on the use of anakinra for the treatment of COVID-19 associated secondary haemophagocytic lymphohistiocytosis. At this time, policy decisions will need to consider data extrapolated from studies assessing anakinra for related conditions.

National Institute for Health and Care Excellence